ENZYME-LINKED-IMMUNOSORBENT-ASSAY (ELISA) FOR IGA AND IGG ANTIBODIES TO EPSTEIN-BARR-VIRUS RIBONUCLEOTIDE REDUCTASE IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA
A. Fonestan et al., ENZYME-LINKED-IMMUNOSORBENT-ASSAY (ELISA) FOR IGA AND IGG ANTIBODIES TO EPSTEIN-BARR-VIRUS RIBONUCLEOTIDE REDUCTASE IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA, International journal of cancer, 59(6), 1994, pp. 739-742
661 bp coding for the carboxyl end of the large sub-unit of EBV ribonu
cleotide reductase was cloned into the pMal plasmid vector. Purified r
ecombinant protein was tested in IgG and IgA ELISAs. For the IgG assay
, 81 out of 100 NPC patients tested positive, whereas for the IgA assa
y, 60 tested positive. Among 100 normal individuals, I tested positive
for the IgG assay and 9 tested positive for the IgA assay. The IgG as
say picked up 6 out of 19 NPC sera which were IFA-VCA- and IFA-EA-nega
tive for IgA antibodies. Hence the recombinant ribonucleotide reductas
e could have good potential as a diagnostic test for NPC or could serv
e as a complementary test to IFA. (C) 1994 Wiley-Liss, Inc.